Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
hVIVO PLC on Tuesday said its half-year profit soared on revenue growth and upped its full-year revenue and earnings margin guidance.
The London-based specialist contract research organisation providing testing for infectious and respiratory vaccines said in the six months to June 30, pretax profit multiplied to £4.3 million from
£453,000 the year before, as revenue surged by 52% to £27.3 million from £18.0 million the year before.
hVIVO upped its full-year revenue guidance by 3.8% to £55 million from£53 million as well as its earnings before interest, tax, depreciation and amortisation margin to around 19%, citing ‘excellent visibility over revenue’ into late 2024.
Chief Executive Officer Yamin Khan said: ‘The first half of 2023 has delivered another period of excellent growth and progress towards our goal of establishing a long-term sustainable growth model. The increasing number of trials, as well as the growing volunteer cohorts and expanding use cases, highlights that the human challenge market is experiencing a strong growth trend that we strongly believe will continue over the long term.’
Shares in hVIVO were up 4.3% at 19.03 pence each in London on Tuesday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.